Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Increasing prevalence of genitourinary disorders
3.2.1.2 Rise in advancement in drug development technology
3.2.1.3 Technological advancement in drug delivery
3.2.2 Industry pitfalls & challenges
3.2.2.1 Competition from non-pharmaceutical therapies
3.2.2.2 Significant side effects associated with genitourinary drugs
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Pipeline analysis
3.7 Porter’s analysis
3.8 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company market share analysis
4.3 Company matrix analysis
4.4 Competitive analysis of major market players
4.5 Competitive positioning matrix
4.6 Strategic dashboard
Chapter 5 Market Estimates and Forecast, By Drug Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Hormonal therapy
5.2.1 Androgen
5.2.2 Estrogen
5.2.3 Other hormonal therapy
5.3 Anti-infective
5.3.1 Antibiotics
5.3.2 Antifungals
5.3.3 Antivirals
5.4 Other drug types
Chapter 6 Market Estimates and Forecast, By Application, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Urinary tract infections (UTIs)
6.3 Benign prostatic hyperplasia (BPH)
6.4 Prostate cancer
6.5 Overactive bladder
6.6 Bladder cancer
6.7 Other applications
Chapter 7 Market Estimates and Forecast, By Route of administration, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Oral
7.3 Parenteral
7.4 Topical
Chapter 8 Market Estimates and Forecast, By Distribution Channel, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospital pharmacies
8.3 Drug store & retail pharmacies
8.4 Online pharmacies
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 Japan
9.4.2 China
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Abbott Laboratories
10.2 Allergan, Inc.
10.3 AstraZeneca Plc
10.4 Bayer AG
10.5 Bristol-Myers Squibb Co.
10.6 Eli Lilly and Company
10.7 F. Hoffmann-La Roche Ltd.
10.8 GlaxoSmithKline Plc
10.9 Ionis Pharmaceuticals, Inc.
10.10 Merck & Co., Inc.
10.11 Novartis AG
10.12 Pfizer, Inc.
10.13 Teva Pharmaceutical Industries Ltd
